Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2022 Summer Meeting | Which subtypes of patients with mesothelioma are most likely to benefit from immunotherapy?

Riyaz Shah • 8 Jul 2022
BTOG 2022 Summer Meeting
Lung Cancer Mesothelioma

Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, UK, discusses which subsets of patients with mesothelioma benefit from immunotherapy. This interview took place at the BTOG 2022 Summer Meeting congress in London.

More from Riyaz Shah

3:17
Key insights from BTOG 2024: MARS 2 and HIT-MESO
Riyaz Shah • 18 Apr 2024
2:42
The benefits of immunotherapy versus chemotherapy: analyzing the results of the IPSOS trial
Riyaz Shah • 28 Apr 2023
2:35
CheckMate-816: what does the data tell us?
Riyaz Shah • 28 Apr 2023
2:49
SYSTEMS-2: radiotherapy in mesothelioma
Riyaz Shah • 28 Apr 2023

Related Videos

0:45
Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton • 18 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals